"Oral Baricitinib Instead Of Topicals For Atopic Dermatitis?" - Andrew Bowser
Baricitinib, a once-daily oral inhibitor of Janus kinase (JAK) 1 and 2, significantly improved the signs and symptoms of atopic dermatitis compared with the placebo arm treated with a topical corticosteroid alone, according to results of a randomized Phase II study. The results, described by Emma Guttman-Yassky, MD, PhD, the Sol and Clara professor of dermatology and clinical immunology and vice chair of research in the department of dermatology at the Icahn School of Medicine at Mount Sinai, provide further evidence that JAK inhibition is a promising targeted strategy that may benefit patients with moderate to severe atopic dermatitis (AD). “I think this potentially provides a new oral treatment that can be used in moderate to severe patients with or without topical steroids,” Dr. Guttman-Yassky said. “It seems efficacious and safe, so we are very excited so far to have a possible new oral therapy for AD to chronically treat our patients.”
- Emma Guttman-Yassky, MD, PhD, The Sol & Clara Professor, Dermatology, Clinical Immunology, Medicine, Vice Chair, Research, Department of Dermatology, Director, The Center for Excellence in Eczema, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai